
ESSA Pharma Inc
NASDAQ:EPIX

FCF Margin
Free Cash Flow Margin
FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
FCF Margin Across Competitors
Country | Company | Market Cap |
FCF Margin |
||
---|---|---|---|---|---|
CA |
![]() |
ESSA Pharma Inc
NASDAQ:EPIX
|
74.1m USD | N/A | |
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-15 953%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
327.9B USD |
27%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
152.5B USD |
32%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
138.3B USD |
33%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.9B USD |
-11%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-394%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
120.8B AUD |
12%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
65.5B USD |
21%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-30%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
38.2B USD |
-3%
|
ESSA Pharma Inc
Glance View
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

See Also
FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
Based on ESSA Pharma Inc's most recent financial statements, the company has FCF Margin of 0%.